V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 260014651 | 260010035 | 1.6 | null | Not known (9) | 2019-08-14 | 2019-08-14 | EP | N | null | 260010022 | CISPLATIN + METHOTREXATE + VINCRISTINE |
| 260014652 | 260010039 | 1.63 | null | null | null | 2015-09-24 | BLEOMYCIN + VINCRISTINE | null | null | 260010054 | METHOTREXATE |
| 260014653 | 260010039 | 1.82 | 92.5 | Palliative (P) | 2018-08-04 | 2018-08-10 | CISPLATIN + ETOPOSIDE + IFOSFAMIDE | N | N | 260010054 | GEMCITABINE + TIP |
| 260014654 | 260010041 | 1.75 | null | null | 2017-07-18 | 2017-07-22 | DA-EPOCH-R | N | N | 260010118 | RMS 2005 TRIAL |
| 260014655 | 260010042 | 1.82 | 71.9 | Disease modification (D) | 2017-02-10 | 2017-02-21 | BLEOMYCIN + CISPLATIN + ETOPOSIDE | N | N | 260010121 | VIP |
| 260014656 | 260010042 | 1.81 | 81 | Palliative (P) | null | 2016-07-10 | Vinblastine weekly | 2 | N | 260010121 | VIP |
| 260014657 | 260010042 | 1.82 | 105 | Curative (C) | 2016-11-22 | 2016-11-28 | Carboplatin + Etoposide IV 3 day | 02 | N | 260010121 | IVA |
| 260014658 | 260010042 | 1.64 | 85.5 | Curative (C) | 2018-02-19 | 2018-03-11 | Methotrexate High Dose (3g/m2) | N | N | 260010121 | DOCETAXEL + TRASTUZUMAB |
| 260014659 | 260010043 | 1.84 | 80.6 | Disease modification (D) | 2015-10-01 | 2015-12-03 | VIP | N | N | 260010206 | IPO |
| 260014660 | 260010044 | 1.73 | 63.6 | Disease modification (D) | 2014-08-21 | 2014-09-25 | RCEOP | N | N | 260010213 | VAI |
| 260014661 | 260010044 | 1.88 | 82.5 | Curative (C) | 2013-10-12 | 2014-02-10 | BLEOMYCIN + VINCRISTINE | N | N | 260010213 | CARBOPLATIN + ETOPOSIDE |
| 260014662 | 260010044 | 1.62 | null | null | null | 2015-09-27 | IFOSFAMIDE + PACLITAXEL | null | null | 260010213 | IFOSFAMIDE + PACLITAXEL |
| 260014663 | 260010044 | 1.68 | 64.9 | Curative (C) | 2018-08-05 | 2018-08-21 | EP | 02 | N | 260010213 | IFOSFAMIDE + PACLITAXEL |
| 260014664 | 260010046 | 1.83 | 81.65 | Curative (C) | 2018-10-26 | 2018-10-26 | DHAP | N | null | 260010335 | CODOX M |
| 260014665 | 260010046 | 1.54 | 107.9 | Adjuvant (A) | 2017-07-12 | 2017-07-12 | ESHAP | 2 | N | 260010335 | FCR |
| 260014666 | 260010049 | 1.83 | 91.75 | Palliative (P) | 2015-12-24 | 2016-01-18 | BLEOMYCIN + CARBOPLATIN + CISPLATIN + VINCRISTINE | N | N | 260010354 | CARBOPLATIN + THIOTEPA + TOPOTECAN |
| 260014667 | 260010050 | 1.93 | 56.45 | null | null | 2014-03-30 | Gemcitabine + Paclitaxel | null | null | 260010354 | CARBOPLATIN + ETOPOSIDE |
| 260014668 | 260010052 | 1.66 | 58.4 | Palliative (P) | 2015-12-12 | 2015-12-12 | Cyclophosphamide High Dose | N | null | 260010413 | TRASTUZUMAB |
| 260014669 | 260010052 | 1.63 | null | Curative (C) | 2019-05-27 | 2019-06-28 | STS Rhabdomyosarcoma RMS 2005 VA | N | N | 260010413 | ACE (GERM CELL) |
| 260014670 | 260010052 | 1.58 | 60 | Curative (C) | 2017-12-05 | 2017-12-06 | BLEOMYCIN + VINCRISTINE | 2 | N | 260010413 | CISPLATIN |
| 260014671 | 260010055 | 1.6 | 52 | Palliative (P) | 2018-02-02 | 2018-02-24 | DOCETAXEL + TRASTUZUMAB | N | null | 260010422 | CYTARABINE HD + METHOTREXATE HD |
| 260014672 | 260010056 | 1.8 | 85.1 | Disease modification (D) | 2016-05-26 | 2016-05-27 | BLEOMYCIN + VINCRISTINE | N | N | 260010488 | ACE (GERM CELL) |
| 260014673 | 260014760 | null | 73.5 | Curative (C) | 2017-03-15 | 2017-03-15 | CVP | N | N | 260010488 | CISPLATIN |
| 260014674 | 260010057 | 1.68 | 108.2 | Disease modification (D) | 2016-08-09 | 2016-11-21 | Docetaxel + Gemcitabine (prior RT) | N | N | 260010561 | CARBOPLATIN + PACLITAXEL |
| 260014675 | 260010059 | 1.84 | null | Palliative (P) | null | 2016-06-07 | BLEOMYCIN + CISPLATIN + VINCRISTINE | null | N | 260010563 | CARBOPLATIN + IFOSFAMIDE + PACLITAXEL |
| 260014676 | 260010060 | 1.73 | 73.6 | Palliative (P) | 2014-04-16 | 2014-06-13 | VIP | 2 | N | 260010581 | CARBO + THIOTEPA + TOPOTECAN |
| 260014677 | 260010061 | 1.79 | 71.2 | Curative (C) | null | 2017-12-03 | IPO | N | N | 260010612 | IFOSFAMIDE + PACLITAXEL |
| 260014678 | 260010062 | 1.63 | 65 | Palliative (P) | 2017-10-28 | 2017-11-05 | CISPLATIN + GEMCITABINE + RITUXIMAB | N | N | 260010620 | NIVOLUMAB |
| 260014679 | 260010062 | 1.67 | 52 | Palliative (P) | 2019-04-07 | 2019-04-13 | Methotrexate High Dose (3g/m2) | N | N | 260010620 | CHOP |
| 260014680 | 260010062 | 1.58 | null | Disease modification (D) | 2015-09-29 | 2015-09-30 | NIVOLUMAB | 02 | N | 260010620 | FEC |
| 260014681 | 260014766 | 1.69 | 131.1 | Palliative (P) | 2018-05-23 | 2018-05-23 | Vinblastine weekly | 02 | N | 260010646 | BLEOMYCIN |
| 260014682 | 260014768 | 1.74 | 93.1 | Palliative (P) | null | 2018-06-01 | BLEOMYCIN + CISPLATIN + ETOPOSIDE + PACLITAXEL | null | null | 260010651 | BLEOMYCIN + CISPLATIN + ETOPOSIDE |
| 260014683 | 260010068 | 1.69 | 77 | Curative (C) | 2018-10-12 | 2018-10-14 | Carboplatin + Paclitaxel (3 weekly) | 2 | N | 260010652 | RMS 2005 TRIAL |
| 260014684 | 260010068 | 1.63 | 116.9 | null | 2017-10-14 | 2017-10-19 | Docetaxel | N | N | 260010652 | AXITINIB |
| 260014685 | 260010069 | 1.83 | 65 | null | 2016-07-25 | 2016-07-28 | BLEOMYCIN + CARBOPLATIN + CISPLATIN + VINCRISTINE | 02 | N | 260010825 | BLEOMYCIN + CISPLATIN + VINCRISTINE |
| 260014686 | 260010071 | 1.81 | 119 | Adjuvant (A) | 2019-06-28 | 2019-06-21 | ACE (germ cell) | 2 | N | 260010825 | PACLITAXEL |
| 260014687 | 260017089 | 1.57 | 73.6 | Adjuvant (A) | 2016-04-20 | 2016-04-27 | Docetaxel 100mg/m2 (21 day) | N | N | 260010857 | METHOTREXATE HIGH DOSE |
| 260014688 | 260010072 | 1.8 | null | Disease modification (D) | 2019-02-26 | 2019-03-31 | BLEOMYCIN + CARBOPLATIN + CISPLATIN + VINCRISTINE | N | N | 260010894 | CARBOPLATIN + VINORELBINE |
| 260014689 | 260010072 | 1.79 | 88 | Disease modification (D) | null | 2016-09-06 | ACE (germ cell) | N | N | 260010894 | RMS 2005 TRIAL |
| 260014690 | 260010073 | 1.84 | 59.5 | Adjuvant (A) | 2017-04-21 | 2017-05-13 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE | N | N | 260010912 | DOXORUBICIN |
| 260014691 | 260010074 | 1.8 | 80.6 | Palliative (P) | 2017-07-31 | 2017-08-03 | Carboplatin + Pemetrexed | 02 | N | 260011034 | CISPLATIN + ETOPOSIDE + IFOSFAMIDE |
| 260014692 | 260010075 | 1.64 | 61.8 | Disease modification (D) | 2016-04-04 | 2016-04-05 | ICE | N | N | 260011034 | CVP |
| 260014693 | 260010076 | 0 | 80.6 | Palliative (P) | 2014-06-21 | 2014-06-21 | CARBOPLATIN + EPIRUBICIN + ETOPOSIDE + MELPHALAN | 02 | N | 260011239 | BLEOMYCIN |
| 260014694 | 260014774 | 1.7 | null | Curative (C) | 2018-10-23 | 2018-10-27 | Carboplatin + Thiotepa + Topotecan | 02 | null | 260011267 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE |
| 260014695 | 260018241 | 1.75 | 68.4 | Palliative (P) | 2016-09-18 | 2016-09-22 | CISPLATIN + ETOPOSIDE + IFOSFAMIDE | 02 | N | 260011287 | CARBOPLATIN + ETOPOSIDE |
| 260014696 | 260018241 | 1.63 | null | Palliative (P) | 2013-06-22 | 2013-06-23 | CISPLATIN + GEMCITABINE + RITUXIMAB | N | N | 260011287 | BLEOMYCIN + VINCRISTINE |
| 260014697 | 260018241 | 1.59 | 68 | Curative (C) | 2015-11-12 | 2015-11-17 | CYCLOPHOSPHAMIDE | N | N | 260011287 | CYCLOPHOSPHAMIDE |
| 260014698 | 260014776 | 1.75 | null | Curative (C) | 2015-01-11 | 2015-01-20 | Carboplatin + Etoposide IV 3 day | N | null | 260011412 | VIP |
| 260014699 | 260010082 | 0 | null | Palliative (P) | 2014-09-01 | 2014-09-01 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | null | 260011419 | GEMCITABINE |
| 260014700 | 260014778 | 1.75 | 77 | Not known (9) | null | 2017-01-18 | BLEOMYCIN + CISPLATIN + VINCRISTINE | N | null | 260011453 | POMB |